| Multiple Myeloma

Carvykti vs Xpovio

Side-by-side clinical, coverage, and cost comparison for multiple myeloma.

Deep comparison between: Carvykti vs Xpovio with Prescriber.AI

AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.

Safety signalsXpovio has a higher rate of injection site reactions vs Carvykti based on FDA-approved prescribing information

Coverage gaps3 major payers require step therapy for Xpovio but not Carvykti, including UnitedHealthcare

Category

Carvykti

Xpovio

At A Glance

RouteIV infusion

FrequencySingle infusion

ClassBCMA-directed CAR-T cell therapy

RouteOral

FrequencyOnce or twice weekly

ClassXPO1 inhibitor

Indications

Multiple Myeloma

Multiple Myeloma
Diffuse Large B-Cell Lymphoma

Dosing

Multiple Myeloma 0.5-1.0x10^6 CAR-positive viable T cells/kg IV (max 1x10^8 cells) as a single infusion, administered 2-4 days after lymphodepleting chemotherapy (cyclophosphamide 300 mg/m^2 IV and fludarabine 30 mg/m^2 IV daily for 3 days); premedicate with acetaminophen and an H1-antihistamine 30-60 minutes prior to infusion.

Multiple Myeloma (with Bortezomib and Dexamethasone) 100 mg orally once weekly on Day 1 of each week in combination with bortezomib 1.3 mg/m2 SC once weekly and dexamethasone 20 mg orally twice weekly on Days 1 and 2.

Multiple Myeloma (with Dexamethasone) 80 mg orally on Days 1 and 3 of each week in combination with dexamethasone 20 mg orally on Days 1 and 3 of each week.

Diffuse Large B-Cell Lymphoma 60 mg orally on Days 1 and 3 of each week until disease progression or unacceptable toxicity.

Contraindications

—

Drug Interactions

26View drug interactions

898View drug interactions

Adverse Reactions

Most common (>20%) Pyrexia, cytokine release syndrome, hypogammaglobulinemia, hypotension, musculoskeletal pain, fatigue, infections-pathogen unspecified, cough, chills, diarrhea, nausea, encephalopathy, decreased appetite, upper respiratory tract infection, headache, tachycardia, dizziness, dyspnea, edema, viral infections, coagulopathy, constipation, vomiting

Serious Pneumonia, cytokine release syndrome, sepsis, encephalopathy, viral infection, cranial nerve palsies

Postmarketing T cell malignancies including T-cell lymphoma, immune effector cell-associated enterocolitis and gastrointestinal perforation, infusion related reactions, JC virus progressive multifocal leukoencephalopathy

Most common (>=20%) Fatigue, nausea, thrombocytopenia, decreased appetite, diarrhea, vomiting, weight decreased, anemia, peripheral neuropathy, upper respiratory tract infection, hyponatremia, cataract

Serious Thrombocytopenia, neutropenia, gastrointestinal toxicity (nausea, vomiting, diarrhea, weight loss), hyponatremia, serious infection (including pneumonia and sepsis), neurological toxicity, cataract

Pharmacology

CARVYKTI is a BCMA-directed, genetically modified autologous T cell immunotherapy that reprograms a patient's own T cells with a transgene encoding a CAR featuring two BCMA-targeting single-domain antibodies, a 4-1BB co-stimulatory domain, and a CD3-zeta signaling domain; upon binding to BCMA-expressing cells, the CAR promotes T cell activation, expansion, and elimination of target cells.

Selinexor reversibly inhibits exportin 1 (XPO1), blocking nuclear export of tumor suppressor proteins and oncogenic mRNAs, causing nuclear accumulation of tumor suppressors, downregulation of oncoproteins such as c-myc and cyclin D1, cell cycle arrest, and apoptosis of cancer cells.

View Full FDA Information

View full FDA information

Enter your patient's insuranceCheck specific coverage details for your patient.

Most Common Insurance

Anthem BCBS

Carvykti